Real stories of migraine-free days with Emgality

Many people smiling in Emgality bubble

View efficacy results in patients with episodic or chronic migraine

Hear from real patients with episodic or chronic migrainea

aPatients were compensated for their time.


Patients with episodic migraine (4-14 migraine headache days [MHDs] per month)1,

Meet Lisa in Emgality bubble with play button

Lisa, a traveler with migraine

Lisa has had episodic migraine for over 33 years.

Meet Bonnie in Emgality bubble with play button

Bonnie, a food enthusiast with migraine

Bonnie has had episodic migraine for nearly 15 years.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.



Patients with chronic migraine (≥15 headache days per month)1,

Meet Lela in Emgality bubble with play button

Leia, a parent with migraine

Leia has had chronic migraine for over 26 years.

Meet Ashley in Emgality bubble with play button

Ashley, a fiancée with migraine

Ashley has had chronic migraine for almost 15 years.

Tally Up calendar with stickers in Emgality bubble

Tally Up helps empower patients to track and celebrate migraine-free days

The Tally Up Journal is a place where your patients can track migraine-free days. Patients also have Information Cards that they may share with friends who are interested in learning about Emgality.

You can request the Tally Up Journal by calling the Emgality Answers Center at 1-833-EMGALITY (1-833-364-2548).

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Meet Bryan in Emgality bubble with play button

Bryan, a man with episodic cluster headache

Bryan was diagnosed about ten years ago.

SELECT IMPORTANT SAFETY INFORMATION
Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Start your patients on Emgality today

View savings carda and additional resources

aGovernmental beneficiaries excluded.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 10DEC2019